Navigation Links
Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
Date:2/26/2013

Beitrag für Krebspatienten leisten wird, und wird seine Entwicklungsbemühungen zur Erweiterung des Anwendungsgebiets daher weiter fortsetzen.

Informationen zu TAS-102
TAS-102 ist ein Antitumormittel, das neben Trifluorthymidin (FTD) auch Nukleosid enthält. Es wird in die DNA integriert und unterdrückt verschiedenste Genfunktionen, die zur Vermehrung von Krebszellen notwendig sind. Hinzu kommt außerdem Tipiracil-Hydrochlorid (TPI), ein Hemmstoff für Thymidinphosphorylase (baut FTD ab), der eine effektive FTD-Konzentration im Blut aufrechterhält. TAS-102 wird zweimal täglich verabreicht und unterliegt einer maximalen täglichen Dosierung von 70 mg/Quadratmeter über fünf Tage, gefolgt von zwei Tagen Pause vor Beginn des zweiten Behandlungszyklus. Im Anschluss folgt eine 14-tägige Ruhephase, sodass sich die Behandlung über einen Gesamtzeitraum von 28 Tagen erstreckt.

Informationen zur klinischen Phase-II-Studie von TAS-102
Die klinische Phase-II-Studie wurde in der Zeit von August 2009 bis April 2010 mit 172 Patienten an 20 medizinischen Einrichtungen in Japan durchgeführt. Die Studie zielt auf einen Bereich ab, für den es in Japan derzeit keine vollständig etablierte Therapie gibt – d. h. Patienten mit metastasierten kolorektalen Karzinomen, die für herkömmliche Chemotherapie unempfänglich sind und mindestens zweimal oder häufiger mit Fluoropyrimidin, Irinotecan und Oxaliplatin behandelt wurden. Nach dem Zufallsprinzip erhielten Patienten entweder TAS-102 (114 Fälle) oder ein Placebo (58 Fälle). Das Gesamtüberleben war der primäre Endpunkt der Studie.

Informationen zur globalen klinischen Phase-III-Studie (RECOURSE)
Bei der globalen klinischen Phase-III-Studie (RECOURSE) handelt es sich um eine rando
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
2. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
3. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
4. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
5. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
6. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
8. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
9. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
10. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
11. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... April 21 Strativa,Pharmaceuticals, the proprietary products ... PRX ) today announced that its development ... a Phase III,study of Loramyc(R) (miconazole Lauriad(R)) ... candidiasis (OPC)., Top line data show ...
... Nostrum, a privately-held,company based in Edison, ... completed its early, primate, proof-of-concept study for ... SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, is ... from the Institute of Microbial,Technology, Chandigarh, India, ...
Cached Medicine Technology:Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 2Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 3Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Wittenberg, MD, uses an,investor,s technology to yield the ... 6 When Scottsdale businessman,Warren Kaplan decided a ... had no,idea that an innovative medical product Possis ... gifted interventional radiologist - save his daughter,s life., ...
... Nov. 6 Repligen Corporation,(Nasdaq: RGEN ) ... Phase 2b,clinical trial to evaluate the use of ... bipolar depression. This Phase 2b study is a,multi-center, ... patients with bipolar depression will receive,either RG2417 or ...
... SALT LAKE CITY, Nov. 6 "In a remarkable ... history of cosmetics, women around the,country have been applying ... of fine lines, wrinkles and crows, feet." Five years ... a revolution in the cosmetic,industry: a little-known American stretch-mark ...
... 6 Performance Health Technologies,Inc. (PHT), a leader ... guide and monitor exercise and rehabilitation, announced,today that ... the September 5 edition of "60 Second Science," ... "Virtual Rehabilitation: Wireless Motion Sensor to Help,Treat That ...
... NEW YORK, Nov. 6 According to the ... The African,American community is one of the groups ... diagnosed. With November being National Diabetes Month,Black Expressions(R) ... that raise,awareness about diabetes and offer information about ...
... Salud to Use Pan-Enterprise Search Platform to,Identify ... and SAN FRANCISCO, November 6 /PRNewswire-FirstCall/,-- Autonomy ... global leader in,infrastructure software for the enterprise ... Spain,s most innovative health service,provider, has selected ...
Cached Medicine News:Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 2Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 2Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 3Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 2Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 3Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 4
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... of diabetes in order to maintain tight control ... way to reduce or even prevent diabetes-related complications. ... a diabetes patients quality of life, however, is ... been the guiding factors in the development of ...
... the CGMS System Gold can assist you ... based on detailed glycemic profiles. Its also ... motivation and collaboration with patients.1, ,While ... all diabetes patients, it may be of ...
... The GlucoWatch G2 Biographer is intended for ... levels in adults (aged 18 and older) ... diabetes. Parents should supervise the use of ... G2 Biographer is intended to supplement, not ...
Medicine Products: